glp 1 drugs

As young and otherwise healthy people turn to GLP-1 drugs to meet weight targets, doctors warn the side-effects can land them in hospital

Docs see patients reporting irritability and loss of drive. The answer may lie in dopamine, the brain’s reward system

A groundbreaking study has unveiled that GLP-1 receptor agonists, a type of weight-loss drug, can decrease cardiovascular incidents by 13% in just under three years. These results remain consistent across different diabetes backgrounds, emphasizing long-lasting perks like diminished risks of heart attacks, strokes, and improved survival rates.

Tech entrepreneur Bryan Johnson, known for his multi-million dollar anti-aging efforts, has revealed 41 accessible health hacks. His advice, honed through extensive experimentation, emphasizes simple, low-cost habits like prioritizing sleep, regular exercise, whole foods, and avoiding detrimental behaviors. Johnson's core message focuses on foundational wellness practices that can significantly impact longevity.

Lower-cost, latest-generation immunotherapies from China are a shot in the arm for Indian cancer patients who have been priced out of treatment by expensive drugs from western MNCs

Storage of fat is different in Indians. This makes our organs vulnerable to inflammation

New research reveals genes influence weight loss and nausea from Ozempic and Mounjaro. A study of nearly 28,000 people found specific genetic variants predict drug effectiveness and side effects. This breakthrough could lead to personalized prescriptions, helping doctors tailor treatments for millions. Doctors may soon use genetic tests to set realistic expectations and choose the best drug for each patient.

The UAE has approved Foundayo (orforglipron), Eli Lilly's once-daily oral obesity pill, becoming one of the first countries globally to offer a needle-free alternative. This GLP-1 receptor agonist mimics natural hormones to regulate appetite and blood sugar, aiding weight loss and improving metabolic health. Available by prescription from May 2026, it's intended for long-term use alongside lifestyle changes.

Rebel Wilson's sustained conversation around her health journey in 2026 highlights a balanced approach to weight loss, emphasising gradual lifestyle changes over strict dieting. While she confirmed trying Ozempic for cravings, her major transformation stemmed from consistent walking, strength training, and mindful eating, reflecting a shift towards health first and self-acceptance.

It is not a quick fix. It is not your ‘next-generation weight-loss drug’. It is not a cosmetic solution or something to include in a pre-wedding routine, experts warn. Despite that, the popularity of Mounjaro continues to quietly reshape the narrative around fitness, beauty and confidence

Affordable generic versions of Ozempic and Wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging Eli Lilly's Mounjaro, with generics and lower pricing boosting semaglutide's market position.

Our relationships, even with ourselves, shift when the blur of alcohol is gone. Vulnerability isn’t outsourced to a fifth glass of wine. Joy becomes less about the shared high, more about shared presence

Once prescribed for diabetes and obesity, GLP-1 drugs are now entering cardiology with evidence of cardiovascular benefits. The shift raises a key question — who truly stands to gain from them?

Online forums are leading Indians to experimental weight-loss drugs not yet approved for use. What follows is a murky chain of Chinese suppliers, local sellers, imports and self-injection that has doctors worried

The Centre has issued a detailed advisory on GLP-1 receptor agonist drugs, emphasizing their use for type 2 diabetes and obesity must be strictly under medical supervision. Authorities are increasing regulatory surveillance and warning of strict action against violations in their sale or prescription.

An Oxford University expert says obesity is less personal failure than a world built for overeating — and GLP-1 drugs show how biological it is. Can India avoid richer countries’ food mistakes?

India's drug regulator is cracking down on the easy availability of GLP-1 weight-loss drugs following nationwide raids. Inspections revealed significant gaps in how these prescription medicines are sold and promoted, with concerns over sales without prescriptions and inadequate medical oversight. Authorities are intensifying enforcement to curb misuse and ensure these drugs are only dispensed under strict medical supervision.

Serena Williams’ promotion of GLP-1 medication has sparked a nuanced debate that blends personal health with public influence. While an influencer’s emotional critique highlights concerns about body image messaging in sports, Williams’ own account emphasizes real medical benefits, including improved blood sugar and reduced cholesterol. The situation reflects a broader tension between transparency and responsibility, especially when elite athletes speak to audiences that extend far beyond sport.

An Indian man hailed Mounjaro as a "miracle" for losing 10 kilos in three months, but revealed a concerning side effect: emotional blunting. He described feeling muted joy and sadness, impacting his personal and professional life. While the drug effectively suppresses appetite, he felt a crucial emotional switch had been turned off, a rarely discussed consequence beyond typical side effects.